Kevin Marks

Kevin Marks currently serves as President and CEO of Delphia Therapeutics and has been with the company since July 2022. Marks co-founded the company and also holds advisory roles at GV, starting in April 2022. Previously, Marks was the Head of Oncology Drug Discovery at Novartis Institutes for BioMedical Research from September 2020 to March 2022, overseeing a team focused on various oncology indications. Marks spent over eleven years at Agios Pharmaceuticals, culminating in the role of Vice President of Biology, where responsibilities included supporting oncology and rare genetic diseases initiatives. Earlier career experiences include senior scientific roles at Makoto Life Sciences and Curis. Marks earned a PhD in Molecular Pharmacology/Chemical & Systems Biology from Stanford University and a BA in Biology from Cornell University.